Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8197974 | 0.84 | PTGS1 (0.70) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL15391717 | 0.79 | PTGS1 (0.70) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL16405262 | 0.79 | MGLL (0.54) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL34464 | 0.79 | PTGS1 (0.70) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL29044909 | 0.79 | MGLL (0.54) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL25414956 | 0.77 | PTGS1 (0.68) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL255340 | 0.77 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL28981238 | 0.77 | PTGS1 (0.68) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL20169556 | 0.77 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL2734915 | 0.77 | MGLL (0.52) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-05-19 | — | — | US | disclosed |
| EP-3908316-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3907237-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | Amgen Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-2935311-B1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186229-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-3674314-A2 | APELIN POLYPEPTIDES | Amgen, Inc (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010093436-A2 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | CARSON DENNIS A (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2162540-A2 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS | Amgen Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | AMGEN INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008153745-A2 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1397339-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-10-16 | — | — | US | disclosed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | HGFAC, HDGF, GRB2 | MGLL 4489/4885FAAH 3850/4885PTGS1 4059/4885 |
| US-20220152188-A1 | TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS | TLR7, TLR4, TLR3 | MGLL 146/4885FAAH 1497/4885PTGS1 2180/4885 |
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | EEA1, PCTP, TTPA | MGLL 1843/4885FAAH 2655/4885PTGS1 501/4885 |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | TLR3, TLR1, TLR6 | MGLL 2260/4885FAAH 3327/4885PTGS1 846/4885 |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | GRPR, CALCRL, CALCA | MGLL 685/4885FAAH 191/4885PTGS1 1085/4885 |
| US-10941182-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | MGLL 3340/4885FAAH 1485/4885PTGS1 3535/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | MGLL 3340/4885FAAH 1485/4885PTGS1 3535/4885 |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | PGD, AADAT, TRHDE | MGLL 2316/4885FAAH 912/4885PTGS1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.